financetom
Business
financetom
/
Business
/
Agilent Technologies Insider Sold Shares Worth $7,844,550, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Agilent Technologies Insider Sold Shares Worth $7,844,550, According to a Recent SEC Filing
Mar 12, 2024 12:07 PM

02:43 PM EDT, 03/12/2024 (MT Newswires) -- Michael R. McMullen, Director, CEO and President, on March 08, 2024, sold 52,297 shares in Agilent Technologies ( A ) for $7,844,550. Following the Form 4 filing with the SEC, McMullen has control over a total of 253,909 shares of the company, with 253,909 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1090872/000112760224009663/xslF345X03/form4.xml

Price: 147.50, Change: +0.21, Percent Change: +0.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US consumer finance watchdog formally kills Biden-era bad actor registry
US consumer finance watchdog formally kills Biden-era bad actor registry
Oct 28, 2025
WASHINGTON (Reuters) -The top U.S. government watchdog for consumer finance has formally scrapped a registry for non-bank financial companies caught violating consumer laws, asserting that its costs outweighed any benefit to the public, according to a government notice issued Tuesday. The repeal of the registry -- which the prior administration of President Joe Biden had said would help catch and...
Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says
Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says
Oct 28, 2025
11:16 AM EDT, 10/28/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) paused patient dosing and screening for its two phase 3 Nex-Z trials after reports of liver toxicity, however, its claim that the issue is specific to the gene target is unconvincing, RBC Capital Markets said in a note Monday. The analysts said that other biotechnology companies, including Alnylam...
Corby Spirit and Wine Names Florence Tresarrieu as President and CEO
Corby Spirit and Wine Names Florence Tresarrieu as President and CEO
Oct 28, 2025
11:19 AM EDT, 10/28/2025 (MT Newswires) -- Corby Spirit and Wine Limited's (CSW-A.TO and CSW-B.TO) board of directors announced Tuesday that, effective Jan. 1, 2026, Florence Tresarrieu has been appointed as president and chief executive officer of Corby, succeeding Nicolas Krantz, who will take on new responsibilities within the Pernod Ricard Group. The company said that Tresarrieu brings over two...
Live Nation Entertainment Renames Toronto's Waterfront Amphitheater as RBC Amphitheatre
Live Nation Entertainment Renames Toronto's Waterfront Amphitheater as RBC Amphitheatre
Oct 28, 2025
11:18 AM EDT, 10/28/2025 (MT Newswires) -- Live Nation Entertainment ( LYV ) said Tuesday it agreed to a multi-year partnership with Royal Bank of Canada ( RY ) to rename the amphitheater at Toronto's waterfront to RBC Amphitheatre, effective immediately, and to transform it into an expanded year-round venue by 2030. RBC Amphitheatre is set to see an increase...
Copyright 2023-2026 - www.financetom.com All Rights Reserved